On October 14, 2021 Veracyte, Inc. (Nasdaq: VCYT) reported that new data further validating the clinical utility of the company’s Decipher Prostate genomic test will be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2021 taking place October 24-27, 2021, in Chicago (Press release, Veracyte, OCT 14, 2021, View Source [SID1234591240]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In two, separate oral presentations, investigators will share findings from studies that assessed the Decipher Prostate test in multiple, large Phase 3 randomized trials. The studies evaluated the test’s utility in patients with newly diagnosed, clinically high-risk prostate cancer receiving definitive radiotherapy as well as among patients experiencing biochemical disease progression following radical prostatectomy.

"The Decipher Prostate data that will be shared at this year’s ASTRO meeting provide exciting new evidence that the test could positively and profoundly impact shared decision-making, resulting in individualized treatment decisions in both the post-biopsy and post-prostatectomy prostate cancer settings," said Tina Nova, Ph.D., Veracyte’s general manager, Thyroid and Urologic Cancers.

Following are details of the abstract presentations:

Dates/Times:

Media Briefing: Monday, October 25, 9:30 – 10:30 a.m. CT

Oral Presentation: Tuesday, October 26, 8:35 a.m. CT

Title:

Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer

Abstract #:

95 (oral presentation)

Presenter:

Paul L. Nguyen, M.D., Dana-Farber / Brigham and Women’s Cancer Center

Location:

McCormick Place West, Room W181 a/b/c

Date/Time:

Tuesday, October 26, 8:25 a.m. CT

Title:

Performance of a Genomic Classifier (GC) within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) after Radical Prostatectomy (RP)

Abstract #:

94 (oral presentation)

Presenter:

Alan Dal Pra, M.D., University of Miami – Sylvester Cancer Center

Location:

McCormick Place West, Room W181 a/b/c